Superworth

Ginkgo Bioworks revenue DNA

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
$111.9M
Latest quarter, Q2 FY26
$20.2M
−48% on a year earlier
Fiscal year 2025
$149.6M
−34% on the year before

Ginkgo Bioworks' revenue was $111.9M over the twelve months to Jun 30, 2026, down 47% on a year earlier.

In its latest quarter, Q2 FY26, it was $20.2M, down 48% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$149.6M−34%
FY2024$227M−10%
FY2023$251.5M−47%
FY2022$477.7M+52%
FY2021$313.8Mn/a
FY2020n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$20.2M−48%$111.9M
Q1 FY26$19.5M−49%$130.8M
Q4 FY25$33.4M−24%$149.6M
Q3 FY25$38.8M−56%$160M
Q2 FY25$39.1M−30%$210.3M
Q1 FY25$38.2M+1%$227.3M
Q4 FY24$43.8M+26%$227M
Q3 FY24$89M+61%$218M
Q2 FY24$56.2M−30%$184.3M
Q1 FY24$37.9M−53%$208.7M
Q4 FY23$34.8M−65%$251.5M
Q3 FY23$55.4M−17%$315M

Against its peers

Companies in Biotechnology nearest Ginkgo Bioworks' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
DNAGinkgo Bioworks$111.9M−47% a year
MGTXMeiraGTx$397.5M
VCELVericel$306.3M+23% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
ADMAAdma Biologics$512.3M+8% a year
Peer median$351.9M

Where Ginkgo Bioworks ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Ginkgo Bioworks

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.